Ownership and insider activity for Stoke Therapeutics, Inc. (STOK): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression.
Price
| Price | $27.91 |
| Market Cap | $1.8B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.8M | $105.4M | $222.5M | $287.3M | $144.9M | $113.6M | $191.4M | $128.0M | $84.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | $74.9M | $116.0M | $10.0M | $88.9M | $200.4M |
| Receivables | 0 | $196000 | $281000 | $6000 | $132000 | $588000 | $64000 | $700000 | $7.9M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $1.9M | $106.1M | $226.0M | $293.9M | $229.2M | $244.1M | $215.3M | $232.8M | $305.7M |
| Property, Plant & Equipment | $473000 | $1.2M | $2.5M | $3.8M | $9.1M | $11.4M | $12.4M | $8.3M | $6.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $2.4M | $107.5M | $228.8M | $297.9M | $238.9M | $256.1M | $228.3M | $271.6M | $418.4M |
| Accounts Payable | $141000 | $1.1M | $751000 | $1.5M | $2.4M | $766000 | $1.7M | $2.5M | $4.9M |
| Short-term Debt | $3.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $3.7M | $2.5M | $4.1M | $11.4M | $17.1M | $31.4M | $30.8M | $40.1M | $57.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $3.7M | $2.5M | $4.3M | $11.8M | $21.1M | $71.2M | $68.8M | $42.5M | $66.0M |
| Retained Earnings | -$13.2M | -$25.7M | -$58.0M | -$110.3M | -$196.1M | -$297.1M | -$401.8M | -$490.8M | -$497.7M |
| Total Equity | -$1.3M | $105.1M | $224.4M | $286.1M | $217.8M | $184.8M | $159.6M | $229.0M | $352.5M |
| Total Debt | $3.0M | 0 | 0 | $1.1M | $5.0M | $2.4M | $2.1M | $4.8M | $3.0M |
| Net Debt | $1.2M | -$105.4M | -$222.5M | -$286.2M | -$214.8M | -$227.2M | -$199.3M | -$212.1M | -$281.7M |
| Working Capital | -$1.8M | $103.7M | $221.9M | $282.5M | $212.1M | $212.7M | $184.5M | $192.7M | $247.8M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 7.69 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 16.42 |
Profitability
| Return on Equity | -59.36% |
| Return on Invested Capital | -62.74% |
| Return on Assets | -52.77% |
| Gross Margin | 84.67% |
| Operating Margin | -809.69% |
| Net Margin | -753.60% |
Related companies: ARDX · BCRX · NTLA · NVAX · PHVS · SYRE · UPB
Explore sector: Healthcare · Biotechnology
More sections of STOK: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks